GENELUX Corp

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

GNLX$1.95-5.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders’ Equity

Genelux Corporation

Condensed Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Treasury Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated
Shares · Amount · Shares · Amount · Capital · Income (Loss) · Deficit · Total
Balance at December 31, 2024	-	34,728,140	$35	(433,333)	$(433)	$278,001	$64	$(251,393)	$26,274
Stock compensation		-	-	-	-	1,423	-	-	1,423
Unrealized loss on investments		-	-	-	-	-	(35)		(35)
Fair value of vested restricted stock units		-	-	-	-	103	-	-	103
Issuance of common shares for cash and warrants, net of costs		3,000,000	3	-	-	9,550	-	-	9,553
Cost of stock option modifications and repricing		-	-	-	-	6	-	-	6
Issuance of common stock in connection with the Company’s equity award programs		5,000	-	-	-	14	-	-	14
Net loss during the three months ended March 31, 2025	-	-	-	-	-	-	-	(7,492)	(7,492)
Balance at March 31, 2025	-	37,733,140	$38	(433,333)	$(433)	$289,097	$29	$(258,885)	$29,846
Stock compensation		-	-	-	-	1,290	-	-	1,290
Unrealized loss on investments		-	-	-	-	-	(26)	-	(26)
Fair value of vested restricted stock units		-	-	-	-	185	-	-	185
Cost of stock option modifications and repricing		-	-	-	-	7	-	-	7
Common stock issued under equity award plans		25,876	-	-	-	52	-	-	52
Net loss during the three months ended June 30, 2025	-	-	-	-	-	-	-	(7,456)	(7,456)
Balance, June 30, 2025	-	37,759,016	$38	(433,333)	$(433)	$290,631	$3	$(266,341)	$23,898

Common Stock · Treasury Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated
	Shares	Amount	Shares	Amount	Capital	Income (Loss)	Deficit	Total
Balance, December 31, 2023	26,788,986	$27	(433,333)	$(433)	$241,389	$14	$(221,524)	$19,473
Stock compensation	-	-	-	-	1,489	-	-	1,489
Unrealized loss on investments	-	-	-	-	-	(19)	-	(19)
Fair value of vested restricted stock units	131,267	-	-	-	989	-	-	989
Issuance of common shares for cash and warrants, net of costs	76,487	-	-	-	688	-	-	688
Cost of stock option modifications and repricing	-	-	-	-	314	-	-	314
Net loss during the three months ended March 31, 2024	-	-	-	-	-	-	(7,850)	(7,850)
Balance, March 31, 2024	26,996,740	$27	(433,333)	$(433)	$244,869	$(5)	$(229,374)	$15,084
Stock compensation	-	-	-	-	1,298	-	-	1,298
Unrealized loss on investments	-	-	-	-	-	(6)	-	(6)
Fair value of vested restricted stock units	-	-	-	-	136	-	-	136
Cost of stock option modifications and repricing	-	-	-	-	6	-	-	6
Issuance of common shares for cash and warrants, net of costs	7,500,000	8	-	-	27,670	-	-	27,678
Common stock issued under equity award plans	15,902	-	-	-	49	-	-	49
Net loss during the six months ended June 30, 2024	-	-	-	-	-	-	(6,576)	(6,576)
Balance, June 30, 2024	34,512,642	$35	(433,333)	$(433)	$274,028	$(11)	$(235,950)	$37,669

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.